TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37790451

Group type: EXPERIMENTAL
Intervention: Rule-based segmentation of contrast-enhancing tumor (CE) and intratumoral Fluid using mpMRI
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Rule-based segmentation of High FLAIR (Edema1 + Edema2)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Model combining time-on-treatment and rule-based volumes of CE and intratumoral Fluid
Number of subjects: 285
Study: 37790490

Group type: EXPERIMENTAL
Intervention: ATL-DC + TLR agonist (poly-ICLC)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ATL-DC + TLR agonist (resiquimod)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ATL-DC
Number of subjects: 23
Study: 37790581

Group type: EXPERIMENTAL
Intervention: RTS,S vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PfSPZ vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primaquine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genotyping methods
Number of subjects: 0
Study: 37790695

Group type: EXPERIMENTAL
Intervention: Oral-motor therapy programme for one month
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 37790949

Group type: EXPERIMENTAL
Intervention: In-person training with technical assistance
Number of subjects: 2877

Group type: EXPERIMENTAL
Intervention: In-person training without technical assistance
Number of subjects: 2877

Group type: COMPARATOR
Intervention: Website access with technical assistance
Number of subjects: 2877
Study: 37791240

Group type: EXPERIMENTAL
Intervention: Healthy eating and gardening intervention
Number of subjects: 0
Study: 37791242

Group type: EXPERIMENTAL
Intervention: Dietary Approaches to Stop Hypertension dietary pattern
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Diet tracking application engagement
Number of subjects: 59
Study: 37791379

Group type: EXPERIMENTAL
Intervention: ChAdOx1-HBV
Number of subjects: 0
Study: 37791419

Group type: EXPERIMENTAL
Intervention: Rapid Antiretroviral Therapy (ART) initiation after diagnosis of AHI
Number of subjects: 20
Study: 37791480

Group type: EXPERIMENTAL
Intervention: Target mean arterial blood pressure of 63 mm Hg and liberal oxygen target
Number of subjects: 789

Group type: COMPARATOR
Intervention: Target mean arterial blood pressure of 77 mm Hg and liberal oxygen target
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Low blood pressure and liberal oxygen target
Number of subjects: 789

Group type: COMPARATOR
Intervention: High blood pressure and liberal oxygen target
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Low mean arterial blood pressure and liberal oxygen target
Number of subjects: 789
Study: 37791610

Group type: EXPERIMENTAL
Intervention: Higher physical quality of life
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Higher mental quality of life
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Gastrointestinal symptom severity
Number of subjects: 195
Study: 37791765

Group type: EXPERIMENTAL
Intervention: pBI-11 DNA vaccine via Tropis biojector
Number of subjects: 0
Study: 37791926

Group type: EXPERIMENTAL
Intervention: eHealth HIV-prevention educational intervention with dating safety content
Number of subjects: 1087

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 1087
Study: 37792065

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX) administered according to the Summary of Product Characteristics
Number of subjects: 928

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX)
Number of subjects: 928
Study: 37792260

Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 160
Study: 37792369

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin
Number of subjects: 10678

Group type: COMPARATOR
Intervention: Uncoated aspirin
Number of subjects: 10678
Study: 37792378

Group type: EXPERIMENTAL
Intervention: Better Together Physician Coaching (4-month web-based group coaching program)
Number of subjects: 1017

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1017
Study: 37792437

Group type: EXPERIMENTAL
Intervention: Health care facilitation program including medical internet support from human personal pilots and digital interventions (Intervention Group - IG)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Only personal support and digital interventions targeting the main symptoms (Active Control Group - ACG)
Number of subjects: 1020

Group type: COMPARATOR
Intervention: Untreated comparison group (CompG)
Number of subjects: 1020
Study: 37792458

Group type: EXPERIMENTAL
Intervention: Spinal ultrasound screening
Number of subjects: 25
Study: 37792612

Group type: EXPERIMENTAL
Intervention: Sarilumab (200 mg, twice-monthly subcutaneous injection) plus a 14-week prednisone taper
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo plus a 52-week prednisone taper
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Sarilumab
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 37792613

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray
Number of subjects: 676

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 676
Study: 37792797

Group type: EXPERIMENTAL
Intervention: ORAF intervention (body-centered program)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 400
Study: 37793085

Group type: EXPERIMENTAL
Intervention: Pertuzumab + Trastuzumab
Number of subjects: 0
Study: 37793101

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available.
Number of subjects: 0
Study: 37793306

Group type: EXPERIMENTAL
Intervention: Acupressure (ST25, CV12, CV6) for twice-daily therapy at 4 min per intervention for 7 days
Number of subjects: 128

Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 128
Study: 37793679

Group type: EXPERIMENTAL
Intervention: Health promotion intervention
Number of subjects: 285
Study: 37793742

Group type: EXPERIMENTAL
Intervention: Glutamic acid (highest vs lowest quartile)
Number of subjects: 3486

Group type: EXPERIMENTAL
Intervention: Aspartic acid (highest vs lowest quartile)
Number of subjects: 3486

Group type: EXPERIMENTAL
Intervention: Gamma-aminobutyric acid (highest vs lowest quartile)
Number of subjects: 3486

Group type: EXPERIMENTAL
Intervention: Glycine (highest vs lowest quartile)
Number of subjects: 3486

Group type: EXPERIMENTAL
Intervention: Log-transformed glutamic acid
Number of subjects: 3486

Group type: EXPERIMENTAL
Intervention: Log-transformed aspartic acid
Number of subjects: 3486

Group type: EXPERIMENTAL
Intervention: Log-transformed gamma-aminobutyric acid
Number of subjects: 3486

Group type: EXPERIMENTAL
Intervention: Log-transformed glycine
Number of subjects: 3486
Study: 37793771

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 2.5 mg/kg intravenously every 21 days
Number of subjects: 325

Group type: COMPARATOR
Intervention: Pomalidomide 4.0 mg daily (days 1-21) and dexamethasone 40.0 mg weekly in a 28-day cycle
Number of subjects: 325
Study: 37793772

Group type: EXPERIMENTAL
Intervention: Daratumumab plus pomalidomide and dexamethasone
Number of subjects: 304

Group type: COMPARATOR
Intervention: Pomalidomide and dexamethasone
Number of subjects: 304
Study: 37793780

Group type: EXPERIMENTAL
Intervention: High-dosed prebiotic fibre
Number of subjects: 59
Study: 37793792

Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) 160 mg subcutaneously every 4 weeks after a 16-week placebo-controlled period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) after switching from placebo at Week 16
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ)
Number of subjects: 0
Study: 37793795

Group type: EXPERIMENTAL
Intervention: CorPath GRX robotic system
Number of subjects: 117
Study: 37793853

Group type: EXPERIMENTAL
Intervention: SGN-B7H4V (vedotin ADC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SGN-B7H4V (vedotin ADC) as monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SGN-B7H4V (vedotin ADC) in combination with anti-PD-1 agent
Number of subjects: 0
Study: 37793919

Group type: EXPERIMENTAL
Intervention: Tele-prehabilitation group using a tablet, two accelerometers, and a balance board (Khymeia, Padova, Italy)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group using a booklet
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Tele-prehabilitation group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 37793933

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (exercise and time-restricted eating)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 167
Study: 37793935

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Alcohol consumption in men
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Alcohol consumption in individuals of African descent
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 610
Study: 37794050

Group type: COMPARATOR
Intervention: HER2-positive patients
Number of subjects: 3582

Group type: EXPERIMENTAL
Intervention: HER2-low patients
Number of subjects: 3582
Study: 37794054

Group type: EXPERIMENTAL
Intervention: AI diagnosis (intervention group)
Number of subjects: 993

Group type: COMPARATOR
Intervention: No AI diagnosis (control group)
Number of subjects: 993
Study: 37794139

Group type: EXPERIMENTAL
Intervention: Iliac bone graft mixed with bone marrow aspirate concentrate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Iliac bone graft alone
Number of subjects: 36
Study: 37794185

Group type: EXPERIMENTAL
Intervention: PTPN2/PTPN1 inhibitor ABBV-CLS-484
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37794220

Group type: EXPERIMENTAL
Intervention: Various treatments from five phase II/III studies (Gem/Cis, Ro96, RC57, ACCEPT, RASH)
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: RC57 treatment
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: RASH treatment
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Previous treatment lines > 1
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Performance status
Number of subjects: 912
Study: 37794246

Group type: EXPERIMENTAL
Intervention: NNS beverages
Number of subjects: 493

Group type: COMPARATOR
Intervention: Water
Number of subjects: 493
Study: 37794275

Group type: EXPERIMENTAL
Intervention: Dermatology Life Quality Index (DLQI)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Scalpdex
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Oral Lichen Planus Symptom Severity Measure (OLPSSM)
Number of subjects: 111
Study: 37794281

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (4000 IU qd)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (70 IU Kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37794334

Group type: EXPERIMENTAL
Intervention: Intermittent supplemental oxygen (SO)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Continuous supplemental oxygen (SO)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Room air (RA)
Number of subjects: 202
Study: 37794395

Group type: EXPERIMENTAL
Intervention: Very low-calorie ketogenic diet (VLCKD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hypocaloric balanced diet (HBD)
Number of subjects: 0
Study: 37794431

Group type: EXPERIMENTAL
Intervention: BCG vaccine (intradermal administration)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 1800
Study: 37794432

Group type: EXPERIMENTAL
Intervention: ACL-IB
Number of subjects: 85

Group type: COMPARATOR
Intervention: ACL-R
Number of subjects: 85
Study: 37794453

Group type: EXPERIMENTAL
Intervention: ESUS recurrence score value ≥ 7
Number of subjects: 238

Group type: COMPARATOR
Intervention: Low-risk group (score 0-4)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Intermediate-risk group (score 5-6)
Number of subjects: 238

Group type: COMPARATOR
Intervention: High-risk group (score ≥ 7)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 238
Study: 37794472

Group type: EXPERIMENTAL
Intervention: ICS tapering regimen (initial ICS dose reduced by 50% for 8 weeks followed by total ICS removal)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard of care (no specific details provided)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: ICS tapering regimen
Number of subjects: 110
Study: 37794480

Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 14730

Group type: COMPARATOR
Intervention: Digital Mammography (DM)
Number of subjects: 14730
Study: 37794523

Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging plus motivational interviewing
Number of subjects: 275

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 275
Study: 37794564

Group type: EXPERIMENTAL
Intervention: Genetic testing with a 385 gene kidney disease panel (Renasight TM test)
Number of subjects: 1623
Study: 37794590

Group type: EXPERIMENTAL
Intervention: Modified cell manufacturing process in first-in-human clinical trial of Cas9-engineered T cells (NCT03399448)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expression of p53
Number of subjects: 0
Study: 37794604

Group type: EXPERIMENTAL
Intervention: Dyadic-based intervention
Number of subjects: 484

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 484
Study: 37794659

Group type: EXPERIMENTAL
Intervention: Intranasal corticosteroids (INCS) - 220 μg triamcinolone acetonide twice daily for 14 days prior to nasal allergen challenge (NAC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control saline challenge
Number of subjects: 20

Group type: COMPARATOR
Intervention: NAC with no treatment intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: NAC with 14 days pre-treatment with saline nasal spray (placebo)
Number of subjects: 20
Study: 37794725

Group type: EXPERIMENTAL
Intervention: Auditory stimulation of sleep slow waves
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no auditory stimulation)
Number of subjects: 0
Study: 37794745

Group type: EXPERIMENTAL
Intervention: Bumetanide oral solution, administered twice daily (BID) for 6 months
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo, administered twice daily (BID) for 6 months
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Bumetanide oral solution
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study: 37794802

Group type: EXPERIMENTAL
Intervention: Machine learning model using clinical, laboratory, and demographic data to predict class of variability.
Number of subjects: 5030

Group type: EXPERIMENTAL
Intervention: Measure of variability in ALSFRS-R scores.
Number of subjects: 5030

Group type: EXPERIMENTAL
Intervention: Reduced set of 16 predictors from the machine learning model.
Number of subjects: 5030

Group type: EXPERIMENTAL
Intervention: Variability in disease progression in fast-progressing patients.
Number of subjects: 5030
Study: 37794803

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin with chemotherapy
Number of subjects: 0
Study: 37794814

Group type: EXPERIMENTAL
Intervention: Sub-epithelial connective tissue graft
Number of subjects: 102
Study: 37794830

Group type: EXPERIMENTAL
Intervention: Empirical treatment for bile acid diarrhoea
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: C4 > 46 ng/mL
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Decision tree combining C4 ≥ 31 ng/mL with ≥1.1 daily watery stools (Bristol type 6 and 7)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Logistic regression model including C4, sum of measured stool bile acids, and daily watery stools
Number of subjects: 251
Study: 37794845

Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA treatment
Number of subjects: 430
Study: 37794870

Group type: EXPERIMENTAL
Intervention: Personalized e-coaching based on baseline activity patterns
Number of subjects: 2458

Group type: EXPERIMENTAL
Intervention: Daily prompts to complete 10,000 steps
Number of subjects: 2458

Group type: EXPERIMENTAL
Intervention: Hourly prompts to stand following inactivity
Number of subjects: 2458

Group type: EXPERIMENTAL
Intervention: Daily instructions to read AHA guidelines
Number of subjects: 2458
Study: 37794868

Group type: EXPERIMENTAL
Intervention: PPG-based wearable
Number of subjects: 92

Group type: COMPARATOR
Intervention: Holter ECG (control)
Number of subjects: 92
Study: 37794880

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy with the Penumbra System (ADAPT)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy with the Penumbra System (ADAPT + 3D)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy with the Penumbra System
Number of subjects: 167
Study: 37794909

Group type: EXPERIMENTAL
Intervention: Guided mindfulness meditation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided yoga
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided brisk walking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (self-directed stress management)
Number of subjects: 0
Study: 37795393

Group type: EXPERIMENTAL
Intervention: Standard-of-care SBRT (24 Gy in 2 fractions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-fraction SBRT (19 Gy in 1 fraction)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EBRT (8 Gy in 1 fraction)
Number of subjects: 0
Study: 37795521

Group type: EXPERIMENTAL
Intervention: Oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine prescribed at baseline.
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Higher risk of acquiring HIV (due to condomless sex, frequent sex, and STIs).
Number of subjects: 486
Study: 37795589

Group type: EXPERIMENTAL
Intervention: Robot-assisted transcranial Doppler (raTCD)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Transthoracic echocardiography (TTE)
Number of subjects: 154
Study: 37795617

Group type: EXPERIMENTAL
Intervention: Invasive endotyping with disclosure of results to the invasive cardiologist
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control group with nondisclosure of results
Number of subjects: 231
Study: 37795682

Group type: EXPERIMENTAL
Intervention: 7-hour indoor event in a nightclub at full capacity, with no masking, prior SARS-CoV-2 test result, or social distancing required.
Number of subjects: 1216

Group type: COMPARATOR
Intervention: Control group (non-attendees) with no exposure to the indoor event.
Number of subjects: 1216

Group type: EXPERIMENTAL
Intervention: Clubbing event exposure (attendees).
Number of subjects: 1216
Study: 37795783

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions (including CBT, behavioral interventions, integrative therapies, humanist therapies, and other psychologically oriented interventions)
Number of subjects: 3992

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions
Number of subjects: 3992
Study: 37795883

Group type: EXPERIMENTAL
Intervention: Closed-Loop Insulin Delivery System
Number of subjects: 0
Study: 37795976

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP2438) with 40 μg of bivalent subtype C gp120 adjuvanted with AS01B
Number of subjects: 160

Group type: COMPARATOR
Intervention: ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with MF59
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (vCP2438) with 200 μg of bivalent subtype C gp120 adjuvanted with AS01B
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 37796016

Group type: EXPERIMENTAL
Intervention: Autologous fecal microbiota transplantation (aFMT)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 37796017

Group type: EXPERIMENTAL
Intervention: Telehealth group Cognitive-Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 44
Study: 37796114

Group type: EXPERIMENTAL
Intervention: CGRP
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: NGF
Number of subjects: 264
Study: 37796117

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Injectable platelet-rich fibrin (i-PRF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment with no injections (Control group)
Number of subjects: 60
Study: 37796398

Group type: EXPERIMENTAL
Intervention: Fruquintinib 3 mg QD 3/1 (n=7)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fruquintinib 5 mg QD 3/1 (n=7)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Fruquintinib 5 mg RP2D (n=6)
Number of subjects: 20
Study: 37796417

Group type: EXPERIMENTAL
Intervention: ARR on interfering medications
Number of subjects: 715

Group type: COMPARATOR
Intervention: ARR off interfering medications
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: ARR on interfering medications (threshold 10 pg/μIU)
Number of subjects: 715

Group type: COMPARATOR
Intervention: ARR off interfering medications (threshold 10 pg/μIU)
Number of subjects: 715
Study: 37796513

Group type: EXPERIMENTAL
Intervention: Tislelizumab, 200 mg intravenously every 3 weeks
Number of subjects: 674

Group type: COMPARATOR
Intervention: Sorafenib tosylate, 400 mg orally twice daily
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Tislelizumab
Number of subjects: 674

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 674
Study: 37796540

Group type: EXPERIMENTAL
Intervention: 20 mg CBN
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg CBN + 10 mg CBD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg CBN + 20 mg CBD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg CBN + 100 mg CBD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37796597

Group type: EXPERIMENTAL
Intervention: Group-based parent training (PT) program
Number of subjects: 0
Study: 37796657

Group type: EXPERIMENTAL
Intervention: Lemborexant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daridorexant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37796764

Group type: EXPERIMENTAL
Intervention: escitalopram (ESC)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: escitalopram (ESC) + aripiprazole (ARI)
Number of subjects: 178

Group type: COMPARATOR
Intervention: escitalopram (ESC) only
Number of subjects: 178